Brokerages remain upbeat on select mid-cap names, highlighting strong growth levers and earnings visibility.Nuvama has initiated coverage on Neuland Laboratories with a Buy rating, citing peptide-led growth and Unit III expansion as key drivers, while projecting a robust FY25–28 CAGR across revenue, EBITDA, and PAT.Meanwhile, Motilal Oswal reiterated its Buy call on L&T Finance, underscoring its balanced growth strategy, digital platform
